Peptide LedgerEvidence · Safety · Status
Scientific still life of laboratory glassware in low warm light

Peptide profile · Metabolic

Tirzepatide

A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with an expanding trial programme across cardiometabolic and sleep-related indications.

FDA-approved
GradeAStrong (multiple RCTs)
Last reviewed 2026-07-28Updated 2026-08-13

Quick facts

Classification
Dual incretin receptor agonist peptide
Target / mechanism
GIP receptor and GLP-1 receptor
Development status
Marketed; active phase 3 programme in additional indications
Regulatory status
FDA-approved
Evidence level
Strong (multiple RCTs)
Therapeutic area
Metabolic / endocrine
Route / formulation
Subcutaneous injection

Also referred to as · GIP/GLP-1 dual agonist

What it is

Tirzepatide is a single engineered peptide that activates two incretin receptors rather than one. It is a prescription medicine available under distinct brand products with distinct indications.

How it works

Simultaneous GIP and GLP-1 receptor activation influences insulin secretion, glucagon dynamics, gastric emptying, and appetite regulation.

The relative contribution of GIP receptor activity to observed weight and glycaemic effects remains an active research question.

What it has been studied for

  • Glycaemic control in type 2 diabetes
  • Chronic weight management
  • Obstructive sleep apnoea in people with obesity
  • Heart failure with preserved ejection fraction and obesity phenotype

Approved uses

  • Type 2 diabetes mellitus as an adjunct to diet and exercise
  • Chronic weight management in defined populations

Safety and side effects

Gastrointestinal adverse effects predominate in trials, most commonly nausea, diarrhoea, vomiting, and constipation, typically during dose escalation.

Labelling addresses pancreatitis, gallbladder events, hypersensitivity reactions, and hypoglycaemia risk when combined with insulin secretagogues.

Warnings and contraindications

Boxed warning for thyroid C-cell tumours based on rodent data; human relevance undetermined.
Not indicated in type 1 diabetes; not a substitute for insulin.
Assessment is required in people with a history of pancreatitis, severe gastrointestinal disease, or diabetic retinopathy.

Compounded / research status

Compounded 'tirzepatide' preparations are not approved products. Regulators have issued repeated warnings about unapproved and counterfeit versions.

Investigational uses

Trials in metabolic liver disease, chronic kidney disease, and cardiovascular outcomes are ongoing or reported at varying stages. Investigational status does not imply approval for those uses.

Frequently asked questions

References

  • FDA prescribing informationU.S. Food and Drug Administration
  • Phase 3 metabolic and weight-management trialsPeer-reviewed clinical literature

Reference entries are editorial placeholders describing source type and origin. Primary documents are linked as each profile is expanded.

Editorial disclaimer

This site is educational and does not provide medical advice, dosing protocols, or treatment recommendations. Regulatory status and evidence strength differ sharply between compounds. A “research use only” label does not indicate that a product is appropriate for human use. Decisions about medicines belong with a qualified clinician.
Back to directory